Wednesday, November 7, 2012
Canada - Canadian researchers find no adverse effects in HIV/AIDS vaccine human clinical trials
VANCOUVER: A preventative HIV/AIDS vaccine under development in Canada has shown no adverse effects so far in human clinical trials, researchers said Tuesday.
The vaccine, SAV001-H, was developed by researchers at the University of Western Ontario in Canada and supported by Sumagen Canada, a company that manages and supports clinical development of the vaccine.
SAV001-H is the only HIV vaccine currently under development in the country and one of only a few in the world, Xinhua news agency reported.
The researchers hoped the progress would pave the way for success in the final phases of clinical testing, which might finally lead to the world's first commercialised HIV vaccine.
The first person who applied clinical study to evaluate the vaccine's safety and tolerability was initiated in March in the US after receiving approval from the US Food and Drug Administration.
Infected men and women aged between 18 to 50 years old were enrolled in this study and randomised into two treatment groups to test the vaccine.
The researchers announced that no adverse effects have been observed in patients subjected to the SAV001-H injection to date and that interim data had shown significant increase in the HIV-1 antibody formations in some patients.
With the current results, the researchers are confident of the safety of SAV001-H and its potency of inducing immune responses in human trials as they prepare to take steps towards the next phases of clinical trials.
HIV/AIDS has killed more than 28 million people worldwide and over 34 million people currently live with the virus infection.
Despite numerous trials around the world to develop vaccines, no vaccine has been commercialised to date.